Longitude Capital Management Co., LLC
SEC-registered investment adviser.
- HQ
- CA
Longitude Capital Management Co., LLC makes venture growth investments in biotechnology, medical technology, and health solutions companies. The firm looks for companies that aim to improve clinical outcomes, enhance patient quality of life, and reduce the cost of care. Its portfolio includes Alentis Therapeutics, Bolt Medical, Murj, Kestra Medical Technology, Ceribell, Vera Therapeutics, Mirum Pharmaceuticals, and Aviceda Therapeutics.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Growth | Not enough dated deals | Growth, Series A, Series B |
| Sectors | Healthtech, Biotech, Medical devices | Not enough dated deals | Biotech, Healthtech, Medical devices, Manufacturing |
| Regions | Not stated | Not enough dated deals | CA, MA |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2001 | 1 | Enterprise SaaS |
| 2008 | 3 | Healthtech, Biotech, Medical devices |
| 2009 | 3 | Biotech, Healthtech |
| 2010 | 5 | Medical devices, Healthtech, Manufacturing |
| 2011 | 3 | Biotech, Healthtech, Medical devices |
| 2012 | 4 | Healthtech, Biotech, Medical devices |
| 2013 | 7 | Biotech, Healthtech, Life sciences and research tools |
| 2014 | 4 | Biotech, Medical devices, Consumer |
| 2015 | 10 | Healthtech, Biotech, Medical devices |
| 2016 | 4 | Biotech, Healthtech |
| 2017 | 8 | Biotech, Healthtech, Medical devices |
| 2018 | 10 | Biotech, Healthtech, Medical devices |
| 2019 | 6 | Biotech, Healthtech, Life sciences and research tools |
| 2020 | 6 | Biotech, Healthtech, Medical devices |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2010 | 0 | 0 | 1 | 0 | 2 |
| 2011 | 0 | 0 | 1 | 0 | 2 |
| 2012 | 0 | 0 | 0 | 1 | 2 |
| 2013 | 0 | 1 | 1 | 2 | 1 |
| 2014 | 0 | 0 | 0 | 0 | 2 |
| 2015 | 0 | 0 | 3 | 3 | 2 |
| 2016 | 0 | 0 | 2 | 0 | 2 |
| 2017 | 0 | 0 | 1 | 3 | 1 |
| 2018 | 0 | 0 | 3 | 4 | 2 |
| 2019 | 0 | 0 | 4 | 0 | 1 |
| 2020 | 0 | 0 | 1 | 1 | 3 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| Longitude 103.8 East, L.P. Longitude Capital makes venture growth investments in biotechnology, medical technology, and health solutions companies that improve clinical outcomes, enhance patient quality of life, and reduce the cost of care. It builds balanced portfolios of clinical-stage and commercial-stage companies using venture capital, royalties, PIPEs, and equity-linked instruments. Inferred from the firm's website | 2025 | $100M (Form D) | Open, writing first checks |
| Longitude Prime Fund II, L.P. Longitude Capital makes venture growth investments in biotechnology, medical technology, and health solutions companies that improve clinical outcomes, enhance patient quality of life, and reduce the cost of care. It builds balanced portfolios of clinical-stage and commercial-stage companies using venture capital, royalties, PIPEs, and equity-linked instruments. Inferred from the firm's website | 2022 | $49.86M to $200M (Form D) | Late investment period |
| Longitude Venture Partners V, L.P. Longitude Capital makes venture growth investments in biotechnology, medical technology, and health solutions companies that improve clinical outcomes, enhance patient quality of life, and reduce the cost of care. It builds balanced portfolios of clinical-stage and commercial-stage companies using venture capital, royalties, PIPEs, and equity-linked instruments. Inferred from the firm's website | 2022 | $206.68M to $600M (Form D) | Late investment period |
| Longitude Prime Fund, L.P. | approx. 2021 | $130M to $141.91M (Form D and SEC adviser filing) | Follow-ons only |
03 · People across funds
- Juliet Tammenoms Bakker, Managing Member of the General Partner
Longitude 103.8 East, L.P. (Named on Form D); Longitude Prime Fund II, L.P. (Named on Form D); Longitude Venture Partners V, L.P. (Named on Form D); Longitude Prime Fund, L.P. (Named on Form D)
- Patrick Enright, Managing Member of the General Partner
Longitude 103.8 East, L.P. (Named on Form D); Longitude Prime Fund II, L.P. (Named on Form D); Longitude Venture Partners V, L.P. (Named on Form D); Longitude Prime Fund, L.P. (Named on Form D)
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026